Novo Nordisk launches multi-month subscriptions for Wegovy obesity drugs as it tries to catch up with Eli Lilly
Novo Nordisk introduces subscription plans for Wegovy obesity drugs.
Novo Nordisk has launched a subscription program for its Wegovy obesity drugs, allowing cash-paying patients to select from three, six, or twelve-month plans that promise lower, predictable monthly costs. This initiative aims to help patients manage treatment expenses and improve adherence, especially as the company prepares for increased competition from Eli Lilly's upcoming oral GLP-1 drug.
Key Takeaways
- 1.
Patients can save up to $1,200 annually on Wegovy injections with subscriptions.
- 2.
The subscription program includes options for three, six, or twelve months.
- 3.
Novo's Wegovy pill faces competition from Eli Lilly's upcoming oral GLP-1 drug.
Get your personalized feed
Trace groups the biggest stories, videos, and discussions into one feed so you can stay current without scanning ten tabs.
Try Trace free